AMETEK Q3 EPS beats, raises FY guidance; agrees to buy Paragon Medical for ~$1.9B

AMETEK INC/

2023-Q3 EPS reported $4.19 revenue$4,866,065,000

Q3 sales $1.62B (+5% YoY); GAAP EPS $1.47; adjusted EPS $1.64 (+13%), record operating margins 27.0%.
Record Q3 operating cash flow $473M (+45% YoY). Raises FY2023 adjusted EPS guidance to $6.31-$6.33 (from $6.18-$6.26).
Agreed to acquire Paragon Medical for ~$1.9B cash; Paragon has ~$500M annual sales in medical components/instruments.
Also acquired Amplifier Research Corp., RF/microwave amplifier maker with ~$60M sales; terms not disclosed.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

AMETEK INC/ reported third quarter ended September 30, 2023 results: revenue $1.62 billion, EPS $1.47 per diluted share. Guidance raised.

Period: third quarter ended September 30, 2023
Revenue: $1.62 billion
EPS: $1.47 per diluted share
Guidance: raised
Result: reported results

Exact text from the filing

AMETEK’s third quarter 2023 sales were $1.62 billion

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

AMETEK INC/ reported financial results for nine months ended September 30, 2023.

Period: nine months ended September 30, 2023
Result: reported results

Exact text from the filing

announcing its financial results for the three and nine months ended September 30, 2023

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

AMETEK INC/ filing history →

Source: SEC EDGAR

accession 0001037868-23-000054

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.